Mediwound announces $27.5 million registered direct offering of ordinary shares priced at-the-market

Yavne, israel, feb. 03, 2023 (globe newswire) -- mediwound ltd. (nasdaq: mdwd) (the “company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchase agreement for the sale and purchase of1,964,286 shares of the company's ordinary shares, par value nis 0.07, at a purchase price of $14 per share, in a registered direct offering. the company expects to close the offering on or about february 7, 2023, subject to the satisfaction of customary closing conditions.
MDWD Ratings Summary
MDWD Quant Ranking